clinical trial

[Blood] Scientists hypothesized that the mechanism responsible was IL-15/N-803 promoting recipient CD8 T cell activation that in turn accelerated donor NK cell rejection.

[Connect Biopharma Holdings Limited] Connect Biopharma Holdings Limited reported positive topline results from the global Phase II clinical trial of CBP-201 administered subcutaneously to adult patients with moderate-to-severe atopic dermatitis.

[Connect Biopharma Holdings Ltd.] Connect Biopharma Holdings Limited announced that it has completed full enrollment of the phase II clinical trial evaluating CBP-307 in adult patients with moderate-to-severe ulcerative colitis.

[Hepatic Cell News] Elevar Therapeutics, Inc. announced that the US FDA has granted rivoceranib with orphan drug designation for the treatment of HCC, the most common primary liver malignancy and is a leading cause of cancer-related death worldwide.

[Stem Cells Translational Medicine] In this review, the gap between the many basic studies and limited clinical trials on stem cell-derived RBCs and platelets is summarized.

[Prilenia Therapeutics B.V. (Business Wire, Inc.)] Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announced that the US FDA has granted Fast Track designation to pridopidine for development as a potential treatment for Huntington’s Disease.